Langerui is a biopharmaceutical company dedicated to the development of novel metabolic checkpoint modulators. Driven by metabolic checkpoints, the product pipeline is globally leading, with new treatment concepts for core varieties, focusing on high-value markets for major chronic diseases such as tumors, autoimmune diseases, neurodegenerative diseases, and inflammation. Recently, Langjierui completed an angel round of financing of RMB 50 million, led by Shenzhen Qianhai Wanrong Red Earth Investment Fund (Limited Partnership), followed by Junshang Capital and Park Science and Technology Innovation Fund. This round of financing will be mainly used to promote the research and development of two Phase I clinical pipeline products of Langjierui.
This article is reproduced from: https://www.itjuzi.com/investevent/13293405
This site is for inclusion only, and the copyright belongs to the original author.